Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
To own Turning Point Brands, you need to believe that its Modern Oral portfolio can grow meaningfully while offsetting regulatory, competitive, and margin pressure. ALP’s launch across 11 European markets reinforces the Modern Oral growth story, but it does not remove the near term execution risk around higher sales and marketing spend or the ongoing exposure to regulatory changes that could quickly reshape category economics.
The most relevant recent announcement is TPB’s upgraded 2026 Modern Oral guidance, with gross sales now guided to US$280 million to US$300 million and net sales to US$210 million to US$225 million. ALP’s expansion into the UK and EU will sit against this higher bar, sharpening attention on whether Modern Oral can scale efficiently without putting sustained pressure on SG&A and net margins.
However, investors should also be aware that heavier Modern Oral investment could amplify the impact of any future regulatory tightening on...
Read the full narrative on Turning Point Brands (it's free!)
Turning Point Brands' narrative projects $940.6 million revenue and $144.9 million earnings by 2029. This requires 25.1% yearly revenue growth and about a $89.5 million earnings increase from $55.4 million today.
Uncover how Turning Point Brands' forecasts yield a $130.00 fair value, a 71% upside to its current price.
Four fair value estimates from the Simply Wall St Community span roughly US$42.93 to US$158.91 per share, showing just how far apart individual views can be. Against that wide range, ALP’s European launch as part of the Modern Oral growth story may influence how you weigh upside potential against the risk that higher spending fails to translate into sustainable margin expansion.
Explore 4 other fair value estimates on Turning Point Brands - why the stock might be worth over 2x more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com